Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Dual IRAK1/4 Inhibitor R906289 Monosodium · R906289

Small molecule · Inhibitor of IRAK1 and IRAK4 · developed by Rigel Pharmaceuticals

Phase 1/2 Most advanced trial
RIGL Developer
1 Registered trials

What is Dual IRAK1/4 Inhibitor R906289 Monosodium?

R906289 Monosodium is an oral dual inhibitor of IRAK1 and IRAK4, kinases involved in innate immune signaling. It is being studied in low-risk myelodysplastic syndromes.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
R906289
Drug type
Small molecule
Targets
IRAK1, IRAK4
Mechanism
Inhibitor of IRAK1 and IRAK4
Therapy area
Hematology
Developer
Rigel Pharmaceuticals (RIGL)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2
UNII
FZC82L3L2B

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05308264 Phase 1/2 Low Risk Myelodysplastic Syndromes Recruiting RIGL

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Low Risk Myelodysplastic Syndromes

Other drugs acting on IRAK1 / IRAK4

More from Rigel Pharmaceuticals

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the RIGL page.

Follow RIGL, the company behind Dual IRAK1/4 Inhibitor R906289 Monosodium

See RIGL's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

RIGL catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.